Tenderwize
Zurück zur Suche

Non-exclusive discount agreements for Adapalen + Benzoylperoxid

GWQ ServicePlus AG·Düsseldorf, Germany·Deadline Nov 10, 2026 · 27 days left·Open·Supplies
Structured notice only
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130 a Abs. 8 SGB V mit der Wirkstoffkombination Adapalen + Benzoylperoxid

60/100

Opportunity Score

Needs reviewLow complexity
SuppliesOpen
Warum diese Bewertung?

Chance

60 / 100

Komplexität

30 / 100

Risikofaktoren

The non-exclusive nature means there is no commitment from insurers to purchase from you; actual revenue depends on mar...

No estimated contract value is provided, making it difficult to assess potential return on investment.

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Eckdaten der Ausschreibung

Öffentlicher Auftraggeber
GWQ ServicePlus AG
Land
Deutschland
CPV
33600000 - Pharmaceutical products
Frist
Nov 10, 2026

Überblick

Moderate opportunity

Wichtige Fakten

  • Supplies contract
  • 1 lot
  • Duration until Dec 2026
  • Non-exclusive discount agreements (Rabattvereinbarungen) for the active ingredient combination Adapalen + Benzoylperoxid under §130a Abs. 8 SGB V.
  • The agreement allows pharmaceutical companies to offer discounts on the specified pharmaceutical product to participating health insurance funds.
Vollständige Zusammenfassung anzeigen

This tender is for non-exclusive discount agreements (Rabattvereinbarungen) for the pharmaceutical combination Adapalen + Benzoylperoxid under §130a Abs. 8 SGB V. The contracting authority, GWQ ServicePlus AG, acts on behalf of German statutory health insurance funds. The procedure is an open admission model (Zulassungsmodell) where any interested pharmaceutical company can join at any time under the same conditions. The initial contract start is 01.04.2025, with a deadline for initial submissions on 10.03.2025. The contract runs until 31.12.2026 with two possible 12-month extensions. No estimated contract value is provided, and no award criteria are specified as this is a non-competitive framework.

Risiken

The non-exclusive nature means there is no commitment from insurers to purchase from you; actual revenue depends on mar...

No estimated contract value is provided, making it difficult to assess potential return on investment.

Wichtige Anforderungen

Technical

  • Must be a pharmaceutical company with authorization for the product.

Administrative

  • Submit signed contract in duplicate, plus evidence of drug approval (from AMIce database), signed self-declaration (Anlage 3), list of PZNs (Anlage 4), and EU regulation...
  • Submission must be in German via postal mail (electronic submission not allowed).

Anforderungen können unvollständig sein.

Auftraggeber

Ort

Düsseldorf, DEU

Auftraggeberprofil

Profil öffnen

Kennung

DE258895210

Tätigkeit

Health

Lose (1)

LOT-0000

Non-exclusive discount agreements for Adapalen + Benzoylperoxid

Non-exclusive discount agreements for the active ingredient combination Adapalen + Benzoylperoxid under §130a Abs. 8 SGB V. The agreement is open to all interested pharmaceutical companies with the relevant product authorization. Contract duration: 01.04.2025 to 31.12.2026, with two possible 12-month extensions.

SuppliesEU fundedElectronic submission

Ort

DEA11, Germany

Dauer

Mar 2025 - Dec 2026

Kategorie

Pharmaceutical products

Frist

Deadline Nov 10, 2026

Vergabedetails

Veröffentlichungsdatum
18 Feb 2025
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
112942-2025

Dokumente (1)

Ähnliche Ausschreibungen